News

Article

Actylis Opens 30,000-square-foot API Manufacturing Facility

Author(s):

Actylis new 30,000-ft² API manufacturing facility is located in Eugene, Ore.

Actylis, a global specialty ingredients manufacturer and supplier, announced the formal opening of its new API manufacturing facility on Feb. 27, 2023. The facility, located in Eugene, Ore., is good manufacturing practice (GMP)-compliant and designed to supply both APIs and excipients at both clinical trial and commercial scale.

“We are excited to have this state-of-the-art facility here in Eugene come on line after such an intensive design and development process,” said Christine Bellmor, site director, in a company press release. “We have [seven] manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3 [third quarter]. We have a number of different reactors to allow flexibility for a variety of chemistries. Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed, and more are underway.”

“We designed this facility specifically to enable us to develop and produce innovative APIs for our customers,” said Gilles Cottier, CEO, Acylis, in the release. “We worked closely with architect firm BCA (Blaise Cacciola Architect) and Coffman Engineering to build a facility that has the most up-to-date technology and equipment available.”

Source: Actylis

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content